We read with interest the paper by Schwarz et al.entitled“Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma:A Multicenter Randomized Noncomparative Phase II Trial(PANACHE01 FRENCH08 PRODI...We read with interest the paper by Schwarz et al.entitled“Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma:A Multicenter Randomized Noncomparative Phase II Trial(PANACHE01 FRENCH08 PRODIGE48 study)”(1).This was a multicentre randomised,non-comparative,phase II trial where 153 patients with upfront resectable pancreatic adenocarcinoma(rPDAC)were randomised in a(2:2:1)fashion to neoadjuvant mFOLFIRINOX(leucovorin,fluorouracil,irinotecan and oxaliplatin),neoadjuvant FOLFOX(leucovorin,fluorouracil and oxaliplatin)or conventional up-front surgery followed by adjuvant chemotherapy.展开更多
文摘We read with interest the paper by Schwarz et al.entitled“Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma:A Multicenter Randomized Noncomparative Phase II Trial(PANACHE01 FRENCH08 PRODIGE48 study)”(1).This was a multicentre randomised,non-comparative,phase II trial where 153 patients with upfront resectable pancreatic adenocarcinoma(rPDAC)were randomised in a(2:2:1)fashion to neoadjuvant mFOLFIRINOX(leucovorin,fluorouracil,irinotecan and oxaliplatin),neoadjuvant FOLFOX(leucovorin,fluorouracil and oxaliplatin)or conventional up-front surgery followed by adjuvant chemotherapy.
